Advertisement

Topics

PubMed Journals Articles About "Piperacillin Tazobactam Alternative Carbapenems Patients" RSS

18:01 EDT 23rd September 2018 | BioPortfolio

Piperacillin Tazobactam Alternative Carbapenems Patients PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Piperacillin Tazobactam Alternative Carbapenems Patients articles that have been published worldwide.

More Information about "Piperacillin Tazobactam Alternative Carbapenems Patients" on BioPortfolio

We have published hundreds of Piperacillin Tazobactam Alternative Carbapenems Patients news stories on BioPortfolio along with dozens of Piperacillin Tazobactam Alternative Carbapenems Patients Clinical Trials and PubMed Articles about Piperacillin Tazobactam Alternative Carbapenems Patients for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Piperacillin Tazobactam Alternative Carbapenems Patients Companies in our database. You can also find out about relevant Piperacillin Tazobactam Alternative Carbapenems Patients Drugs and Medications on this site too.

Showing "Piperacillin tazobactam alternative carbapenems patients" PubMed Articles 1–25 of 36,000+

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.

Extended-spectrum β-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum β-lactamase producers.


Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature.

Pipercillin-tazobactam is a frequently used antibiotic that has a broad spectrum of antibacterial activity. The development of severe thrombocytopenia following the use of piperacillin-tazobactam is unusual. Several mechanisms have been proposed for the pathogenesis of thrombocytopenia in this setting which include immune and non-immune causes. Multiple case reports have shown the ability of piperacillin-tazobactam to cause drug-induced immune thrombocytopenia, likely through formation of antibodies that re...

Assessing Antimicrobial Stewardship Initiatives: Clinical Evaluation of Cefepime or Piperacillin-tazobactam in Patients with Bloodstream Infections Secondary to AmpC Producing Organisms.

Management of organisms harboring AmpC beta-lactamases remains challenging. Carbapenems are often considered first-line agents. Due to growing concern for carbapenem resistant Enterobacteriaceae, integrating non-carbapenem strategies is being explored for these pathogens. The primary objective of this study was to evaluate clinical outcomes in patients with bacteremia secondary to AmpC producing organisms treated with cefepime or piperacillin-tazobactam.


Comparative incidence and excess risk of acute kidney injury in hospitalized patients receiving vancomycin and piperacillin-tazobactam in combination or as monotherapy.

Combination therapy with vancomycin and piperacillin-tazobactam has been associated with increased risk of acute kidney injury (AKI) as compared to monotherapy. This study was conducted to assess the comparative incidence of AKI due to combination therapy in patients receiving vancomycin and piperacillin-tazobactam in combination or as monotherapy.

Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit.

The objective of this study was to evaluate AKI incidence with concomitant vancomycin and piperacillin/tazobactam (PTZ) compared to vancomycin and cefepime (FEP) in critically ill patients.

Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.

To determine whether augmented renal clearance (ARC) impacts negatively on piperacillin-tazobactam unbound concentrations in critically ill patients receiving 16 g/2 g/day administered continuously.

Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study.

Recent studies in adults have found an incidence of acute kidney injury (AKI) in patients treated with a combination of vancomycin and piperacillin-tazobactam (TZP) that is greater than that expected with either medication alone. The purpose of this study was to determine whether combination therapy with vancomycin and TZP is associated with an incidence of AKI in pediatric patients higher than that in those on combination therapy with vancomycin and cefepime.

Hematologic Adverse Effects of Prolonged Piperacillin-Tazobactam Use in Adults.

Key words: Neutropenia; Leukopenia; Eosinophilia; Piperacillin-tazobactam; Adverse effects.

Efficacy of Antibiotic Prophylaxis against ventilator-associated pneumonia.

Ventilator-associated pneumonia (VAP) is one of the most important problems of intensive care units. 84 neurologic patients with acute stroke (Glasgow Coma Score ≤ 8) were entered into a double-blind clinical trial. Patients in the intervention group received piperacillin-tazobactam 4g/0.5g at the time of intubation and 12 hours later. The incidences of early-onset (within 4 days of intubation) and late-onset VAP were 9.2 and 26.9 episodes/1,000 days of mechanical ventilation in the intervention and contr...

In-vitro detection of Candida and Aspergillus antigen in parenteral nutrition and fixed combinations of piperacillin-tazobactam.

Screening for Aspergillus (Asp-AG) and Candida antigen (Ca-AG) with immunoassays is established for stem cell recipients at high risk for invasive fungal infections (IFI). While parenteral nutrition (PN) will be applied in case of complications leading to insufficient alimentation, piperacillin-tazobactam (TZP) is started at the onset of febrile neutropenia.

Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis.

As a tricyclic glycopeptide antibiotic used to treat acute infections, Vancomycin (VAN) is often administered with piperacillin/tazobactam (PT) to treat various infections in clinical practice. However, whether the combination of these two drugs, compared to VAN alone, can cause an increased risk of acute kidney injury (AKI) remains controversial.

Nephrotoxicity of piperacillin-tazobactam combined with vancomycin: Should it be a concern?

The combination of piperacillin-tazobactam (pip-tazo) and vancomycin provides a wide spectrum of activity against many pathogens acquired in the health-care setting. However, there have been reports of increased potential for nephrotoxicity with this combination. The aim of this study was to evaluate the nephrotoxic effect of pip-tazo plus vancomycin and compare it with that of pip-tazo and vancomycin alone, and meropenem plus vancomycin, another broad-spectrum combination. A total of 402 patients receiving...

Selection of hyperproduction of AmpC and SME-1 in a carbapenem-resistant Serratia marcescens isolate during antibiotic therapy.

Antibiotic selective pressure may result in changes to antimicrobial susceptibility throughout the course of infection, especially for organisms that harbour chromosomally encoded AmpC β-lactamases, notably Enterobacter spp., in which hyperexpression of ampC may be induced following treatment with cephalosporins. In this study, we document a case of bacteraemia caused by a blaSME-1-harbouring Serratia marcescens that subsequently developed resistance to expanded-spectrum cephalosporins, piperacillin/tazoba...

Potential for More Rational Use of Antibiotics in Hospitalized Children in a Country with Low Resistance - Data From Eight Point Prevalence Surveys.

Antimicrobial resistance (AMR) is low in Norway, but to prevent an increase the Norwegian Government has launched a National Strategy including a 30% reduction of broad-spectrum antibiotics (BSA) in hospitals within 2020. BSA are defined as second- and third-generation cephalosporins, carbapenems, piperacillin/tazobactam and quinolones. There are no recent studies of antibiotic use in Norwegian hospitalized children.

A national quality incentive scheme to reduce antibiotic overuse in hospitals: evaluation of perceptions and impact.

In 2016/2017, a financially linked antibiotic prescribing quality improvement initiative Commissioning for Quality and Innovation (AMR-CQUIN) was introduced across acute hospitals in England. This aimed for >1% reductions in DDDs/1000 admissions of total antibiotics, piperacillin/tazobactam and carbapenems compared with 2013/2014 and improved review of empirical antibiotic prescriptions.

Therapeutic drug monitoring of piperacillin and tazobactam by RP-HPLC of residual blood specimens.

Sepsis is a common diagnosis in critical care with inpatient mortality rates up to 50%. Sepsis care is organized around source control, antibiotics, and supportive care. Drug disposition is deranged by changes in volume of distribution and regional blood flow, as well as multiple organ failure. Thus, assuring that each patient with sepsis attains pharmacokinetic targets is challenging. There is currently no commercially available FDA-approved assay to measure piperacillin-tazobactam, very commonly used as a...

A rapid, LC-MS/MS assay for quantification of piperacillin and tazobactam in human plasma and pleural fluid; application to a clinical pharmacokinetic study.

Piperacillin, in combination with tazobactam is a common first-line antibiotic used for the treatment of pleural infection, however its pleural pharmacokinetics and penetration has not previously been reported. The objective of this work was to develop and validate a rapid and sensitive liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay for quantification of piperacillin (PIP) and tazobactam (TAZ). PIP and TAZ were extracted from both human plasma and pleural fluid samples by protein preci...

Generalized fixed drug eruption to piperacillin/tazobactam and review of literature.

Fixed drug eruption (FDE) is an adverse drug reaction characterized by the development of well-circumscribed, round, dusky erythematous macules and plaques on cutaneous or mucosal surfaces. The reaction occurs on the same mucosal or cutaneous site with subsequent exposures to the offending drug. Although FDE usually manifests as a single lesion, in rare instances, more than one lesion may arise and this is referred to as a generalized eruption. Herein, we present a 31year-old man with history of cystic fibr...

Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration.

Piperacillin is a β-lactam penicillin antibiotic commonly used for the empirical therapy of sepsis and other hospital-acquired infections. However, knowledge regarding the effect of sustained low-efficiency diafiltration (SLED-f), a technique increasingly being used in ICUs, on piperacillin pharmacokinetics (PK) and dosing in critically ill patients is lacking.

Carbapenems versus alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis.

Carbapenems have demonstrated efficacy in treating nosocomial pneumonias in clinical trials despite a reported low lung penetration compared to other β-lactams. Preserving the clinical activity of carbapenems through stewardship efforts is essential. This review aims to identify if differences in outcomes exist, potentially as a function of decreased penetration.

Evaluation of a Risk-guided Strategy for Empiric Carbapenem Use in Febrile Neutropenia.

Febrile neutropenia (FN) is associated with substantial morbidity and necessitate empiric broad spectrum antibiotic treatment. We evaluated a risk-guided FN management strategy using empiric piperacillin-tazobactam and carbapenem in a prospective cohort study. The analysis involved 723 FN episodes in hospitalised adult patients, including those with severe sepsis or prior infection/colonisation with extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Propensity score matching analysis was ...

Incidence of acute kidney injury among critically ill patients with brief empiric use of anti-pseudomonal beta-lactams with vancomycin.

Nephrotoxins contribute to 20-40% of acute kidney injury (AKI) cases in the intensive care unit (ICU). The combination of piperacillin/tazobactam and vancomycin (PTZ/VAN) has been identified as nephrotoxic, but existing studies focus on extended durations of therapy rather than the brief empiric courses often used in the ICU.

Determination of antibiotic resistance pattern and prevalence of OXA-type carbapenemases among Acinetobacter baumannii clinical isolates from inpatients in Isfahan, central Iran.

Acinetobacter baumannii is one of the most important bacterial species with the ability to produce OXA-type carbapenemases. We aimed to evaluate the prevalence of OXA-type carbapenemases among clinical isolates of A. baumannii in three major hospitals of Isfahan. In this cross-sectional descriptive study, 153 non-repeated strains of A. baumannii were isolated from various clinical samples of hospitalized patients in Al-Zahra, Imam Mousa Kazem, and Shariati hospitals from October 2015 to October 2016. Antimi...

Characterization of SPR994, an Orally Available Carbapenem, with Activity Comparable to Intravenously Administered Carbapenems.

Carbapenems are potent antibacterials with broad-spectrum activity. However, poor oral absorption generally confines this important drug class to in-hospital use by intravenous (IV) administration. The continued rise in drug resistant pathogens creates a need for alternative oral therapies with broad-spectrum activity. SPR994 is a novel formulation of the orally bioavailable pivoxil prodrug of SPR859 (tebipenem) and is being developed as the first oral carbapenem for treatment of complicated urinary tract i...

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.

Although the TEM-1 β-lactamase (Bla) hydrolyzes penicillins and narrow-spectrum cephalosporins, organisms expressing this enzyme are typically susceptible to β-lactam/β-lactamase inhibitor combinations such as piperacillin-tazobactam (TZP). However, our previous work led to the discovery of 28 clinical isolates of resistant to TZP that contained only One of these isolates, 907355, was investigated further in this study. 907355 exhibited significantly higher β-lactamase activity and Bla protein level...


Advertisement
Quick Search
Advertisement
Advertisement